• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫功能低下宿主治疗过程中对奥司他韦和帕拉米韦耐药的大流行 H1N1 病毒的快速选择。

Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.

机构信息

Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-3203, USA.

出版信息

Clin Infect Dis. 2010 May 1;50(9):1252-5. doi: 10.1086/651605.

DOI:10.1086/651605
PMID:20345239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2946636/
Abstract

Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.

摘要

已报告含有神经氨酸酶抑制剂耐药突变 H275Y 的 2009 年大流行 H1N1 病毒分离株。我们描述了在 2 例免疫功能低下患者中治疗 9 和 14 天时治疗过程中 H275Y 耐药突变的快速选择，以及首例描述的珀那必利临床显著耐药病例。

相似文献

1
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.免疫功能低下宿主治疗过程中对奥司他韦和帕拉米韦耐药的大流行 H1N1 病毒的快速选择。
Clin Infect Dis. 2010 May 1;50(9):1252-5. doi: 10.1086/651605.
2
Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.宿主细胞对流感神经氨酸酶变体的选择：对 A(H1N1)病毒药物耐药性监测的影响。
Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.
3
Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.在接受静脉注射帕拉米韦治疗的造血细胞移植受者中H275Y突变的早期出现。
Transpl Infect Dis. 2010 Dec;12(6):513-7. doi: 10.1111/j.1399-3062.2010.00582.x. Epub 2010 Nov 10.
4
Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.日本大流行及大流行后期四个季节中分离的耐神经氨酸酶抑制剂的甲型 H1N1pdm09 流感病毒的特征。
Influenza Other Respir Viruses. 2013 Nov;7(6):1390-9. doi: 10.1111/irv.12132. Epub 2013 Jun 8.
5
A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.日本 2013 年 11 月至 12 月出现的具有交叉耐药性的甲型 H1N1pdm09 流感病毒社区集群
Euro Surveill. 2014 Jan 9;19(1):20666. doi: 10.2807/1560-7917.es2014.19.1.20666.
6
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016.甲型 H1N1pdm09 流感病毒因 H275Y/G147R 双重突变而对奥司他韦和帕拉米韦产生交叉耐药性增强，日本，2016 年 3 月。
Euro Surveill. 2016 Jun 16;21(24). doi: 10.2807/1560-7917.ES.2016.21.24.30258.
7
Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.神经氨酸酶蛋白 I223 残基突变对 2009 年大流行流感病毒耐药谱、复制水平和毒力的影响。
Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11. Epub 2011 Dec 27.
8
Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.重组抗流感神经氨酸酶抑制剂的甲型 H1N1 流感病毒的产生和鉴定。
J Infect Dis. 2011 Jan 1;203(1):25-31. doi: 10.1093/infdis/jiq010.
9
Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.从一名人类患者中分离到神经氨酸酶活性位点具有 H273Y 点突变的乙型流感病毒。
J Clin Microbiol. 2012 Jul;50(7):2500-2. doi: 10.1128/JCM.00682-12. Epub 2012 Apr 25.
10
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.大洋洲、东南亚和南非地区对奥司他韦耐药的甲型H1N1流感病毒的出现与传播
Antiviral Res. 2009 Jul;83(1):90-3. doi: 10.1016/j.antiviral.2009.03.003. Epub 2009 Mar 24.

引用本文的文献

1
Targeted protein degradation: advances in drug discovery and clinical practice.靶向蛋白降解：药物发现和临床实践的进展。
Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.
2
Non-Steroidal Estrogens Inhibit Influenza Virus by Interacting with Hemagglutinin and Preventing Viral Fusion.非甾体雌激素通过与血凝素相互作用抑制流感病毒并阻止病毒融合。
Int J Mol Sci. 2023 Oct 19;24(20):15382. doi: 10.3390/ijms242015382.
3
An Isomer of Galidesivir That Potently Inhibits Influenza Viruses and Members of the Order.一种能有效抑制流感病毒及该目成员的加利西韦异构体。
ACS Med Chem Lett. 2023 Mar 30;14(4):506-513. doi: 10.1021/acsmedchemlett.3c00048. eCollection 2023 Apr 13.
4
Vitisin B inhibits influenza A virus replication by multi-targeting neuraminidase and virus-induced oxidative stress.葡萄素B通过多靶点作用于神经氨酸酶和病毒诱导的氧化应激来抑制甲型流感病毒复制。
Acta Pharm Sin B. 2023 Jan;13(1):174-191. doi: 10.1016/j.apsb.2022.07.001. Epub 2022 Jul 6.
5
Discovery of Novel Boron-Containing -Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant.发现新型含硼取代的奥司他韦衍生物作为抗流感 A 病毒药物，用于克服 N1-H274Y 奥司他韦耐药性。
Molecules. 2022 Sep 29;27(19):6426. doi: 10.3390/molecules27196426.
6
Influenza A Virus Neuraminidase Inhibitors.甲型流感病毒神经氨酸酶抑制剂。
Methods Mol Biol. 2022;2556:321-353. doi: 10.1007/978-1-0716-2635-1_21.
7
Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2.针对甲型流感病毒和 SARS-CoV-2 关键保守病毒 RNA 二级结构的可编程抗病毒药物。
Nat Med. 2022 Sep;28(9):1944-1955. doi: 10.1038/s41591-022-01908-x. Epub 2022 Aug 18.
8
Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus.不同药物组合对感染甲型H3N2流感病毒的免疫缺陷小鼠的影响。
Microorganisms. 2020 Dec 11;8(12):1968. doi: 10.3390/microorganisms8121968.
9
In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients.从免疫功能低下患者中分离出的携带双重神经氨酸酶突变的甲型H1N1pdm09多药耐药流感病毒的体外特性研究
Pathogens. 2020 Sep 2;9(9):725. doi: 10.3390/pathogens9090725.
10
miR-1975 serves as an indicator of clinical severity upon influenza infection.miR-1975 可作为流感感染临床严重程度的指标。
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):141-149. doi: 10.1007/s10096-020-04008-1. Epub 2020 Aug 19.

本文引用的文献

1
Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host.免疫功能低下宿主中传播性多重耐药性甲型流感病毒 A/H3N2 的快速选择。
J Infect Dis. 2010 May 1;201(9):1397-403. doi: 10.1086/651610.
2
Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.预防期间出现对奥司他韦耐药的大流行性H1N1病毒。
N Engl J Med. 2009 Dec 3;361(23):2296-7. doi: 10.1056/NEJMc0910060. Epub 2009 Nov 11.
3
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.帕拉米韦用于治疗2009年甲型H1N1流感的紧急使用授权。
N Engl J Med. 2009 Dec 3;361(23):2204-7. doi: 10.1056/NEJMp0910479. Epub 2009 Nov 2.
4
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.2009年北卡罗来纳州两名接受预防治疗的夏令营营员感染对奥司他韦耐药的2009年甲型H1N1大流行性流感病毒
MMWR Morb Mortal Wkly Rep. 2009 Sep 11;58(35):969-72.
5
Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift.除抗原漂变外，新型选择因素驱动近期人类甲型H3N2流感病毒进化。
J Infect Dis. 2009 Oct 15;200(8):1232-41. doi: 10.1086/605893.
6
Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.2009年，华盛顿州西雅图市两名免疫功能低下患者感染对奥司他韦耐药的新型甲型H1N1流感病毒
MMWR Morb Mortal Wkly Rep. 2009 Aug 21;58(32):893-6.
7
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.更新：2009年4月猪源甲型流感（H1N1）病毒的药敏情况
MMWR Morb Mortal Wkly Rep. 2009 May 1;58(16):433-5.
8
A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.一种在临床甲型H3N2流感病毒中导致对奥司他韦耐药的新型神经氨酸酶缺失突变。
J Infect Dis. 2009 Jan 15;199(2):180-3. doi: 10.1086/595736.
9
Pandemic and seasonal influenza: therapeutic challenges.大流行和季节性流感：治疗挑战。
Drug Discov Today. 2008 Jul;13(13-14):590-5. doi: 10.1016/j.drudis.2008.03.024. Epub 2008 May 15.
10
Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.用帕拉米韦和扎那米韦体外筛选出的耐药重组甲型H1N1流感病毒的特性
Antiviral Res. 2007 May;74(2):159-62. doi: 10.1016/j.antiviral.2006.10.012. Epub 2006 Nov 20.